These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. HPV vaccination: are we initiating too late? Hofstetter AM, Stockwell MS, Al-Husayni N, Ompad D, Natarajan K, Rosenthal SL, Soren K. Vaccine; 2014 Apr 07; 32(17):1939-45. PubMed ID: 24530404 [Abstract] [Full Text] [Related]
5. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. Kim J, Bell C, Sun M, Kliewer G, Xu L, McInerney M, Svenson LW, Yang H. CMAJ; 2016 Sep 06; 188(12):E281-E288. PubMed ID: 27378467 [Abstract] [Full Text] [Related]
6. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, Netterlid E, Sparén P, Arnheim-Dahlström L. JAMA; 2014 Feb 12; 311(6):597-603. PubMed ID: 24519299 [Abstract] [Full Text] [Related]
10. Human papillomavirus vaccination and cervical cytology in young minority women. Brogly SB, Perkins RB, Zepf D, Longtine J, Yang S. Sex Transm Dis; 2014 Aug 12; 41(8):511-4. PubMed ID: 25013981 [Abstract] [Full Text] [Related]
11. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Sankaranarayanan R, Joshi S, Muwonge R, Esmy PO, Basu P, Prabhu P, Bhatla N, Nene BM, Shaw J, Poli URR, Verma Y, Zomawia E, Pimple S, Tommasino M, Pawlita M, Gheit T, Waterboer T, Sehr P, Pillai MR, Indian HPV vaccine study group. Vaccine; 2018 Aug 06; 36(32 Pt A):4783-4791. PubMed ID: 29551226 [Abstract] [Full Text] [Related]
14. Prevalence of high-risk human papillomavirus (HR-HPV) infection among women with normal and abnormal cervical cytology in Myanmar. Mu-Mu-Shwe, Harano T, Okada S, Aye-Aye-Win, Khin-Saw-Aye, Hlaing-Myat-Thu, Mo-Mo-Win, Khin-Khin-Oo, Myo-Khin. Acta Med Okayama; 2014 Aug 06; 68(2):79-87. PubMed ID: 24743783 [Abstract] [Full Text] [Related]
15. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study. Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-Dahlström L. Int J Cancer; 2016 Jun 15; 138(12):2867-74. PubMed ID: 26856527 [Abstract] [Full Text] [Related]
16. Effectiveness of school-based and high-risk human papillomavirus vaccination programs against cervical dysplasia in Manitoba, Canada. Righolt CH, Bozat-Emre S, Mahmud SM. Int J Cancer; 2019 Aug 01; 145(3):671-677. PubMed ID: 30653261 [Abstract] [Full Text] [Related]
20. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Basu P, Malvi SG, Joshi S, Bhatla N, Muwonge R, Lucas E, Verma Y, Esmy PO, Poli URR, Shah A, Zomawia E, Pimple S, Jayant K, Hingmire S, Chiwate A, Divate U, Vashist S, Mishra G, Jadhav R, Siddiqi M, Sankaran S, Prabhu PR, Kannan TPRA, Varghese R, Shastri SS, Anantharaman D, Gheit T, Tommasino M, Sauvaget C, Pillai MR, Sankaranarayanan R. Lancet Oncol; 2021 Nov 01; 22(11):1518-1529. PubMed ID: 34634254 [Abstract] [Full Text] [Related] Page: [Next] [New Search]